Lithium specificity in bipolar illness: A classic agent for the classic disorder

Bipolar Disorders

Volumn 11, Issue SUPPL. 2, 2009, Pages 34-44

  Gershon, Samuel ^a,b   Chengappa, K N Roy ^a   Malhi, Gin S ^c,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Bipolar disorder; Classic disorder; John Cade; Lithium; Major depression; Specificity

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; GLYCOGEN SYNTHASE KINASE INHIBITOR; IMIPRAMINE; LITHIUM SALT; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUICIDE;

ANTIMANIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LITHIUM COMPOUNDS;

EID: 66649103006     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00709.x     Document Type: Review

References (132)

1. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychartr Clin North Am 1999; 22: 517-534.
2. Akiskal HS, Azorin JM, Hantouche EG. Proposed multidimensional structure of mania: Beyond the euphoric-dysphoric dichotomy. J Affect Disord 2003; 73: 7-18.
3. Ghaemi SN, Baldessarini RJ. The manic-depressive spectrum and mood stabilization: Kraepelin's ghost. Psychother Psychosom 2007; 76: 65-69.
4. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002; 47: 125-134.
5. Kraepelin E ed. Lectures on Clinical Psychiatry. 3rd English Edition. New York: William Wood & Co, 1913.
6. Benazzi F. Bipolar disorder -focus on bipolar II disorder and mixed depression. Lancet 2007; 369: 935-945.
7. Endicott J, Nee J, Andreasen N, Clayton P, Keller M, Coryell W. Bipolar II. Combine or keep separate? J Affect Disord 1985; 8: 17-28.
8. Coryell W, Endicott J, Reich T, Andreasen N, Keller M. A family study of bipolar II disorder. Br J Psychiatry 1984; 145: 49-54.
9. Coryell W, Keller M, Endicott J, Andreasen N, Clayton P, Hirschfeld R. Bipolar II illness: Course and outcome over a five-year period. Psychol Med 1989; 19: 129-141.
10. Coryell W, Endicott J, Winokur G et al. Characteristics and significance of untreated major depressive disorder. Am J Psychiatry 1995; 152: 1124-1129.
11. Berk M, Dodd S, Malhi GS. 'Bipolar missed states': The diagnosis and clinical salience of bipolar mixed states. Aust N Z J Psychiatry 2005; 39: 215-221.
12. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: Implications for the antidepressant-suicide controversy. J Affect Disord 2005; 85: 245-258.
13. Benazzi F. Is there a continuity between bipolar and depressive disorders? Psychother Psychosom 2007; 76: 70-76.
14. Vieta E, Phillips ML. Deconstructing bipolar disorder: A critical review of its diagnostic validity and a proposal for DSM-V and ICD-11. Schiz Bull 2007; 33: 886-892.
15. National Institute for Health and Clinical Excellence. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care: Clinical Guideline 38. London: NHS, 2006.
16. Kowatch RA, Fristad M, Birmaher B et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adoles Psychiatry 2005; 44: 213-235.
17. National Institute of Mental Health (NIMH). Research roundtable on prepubertal bipolar disorder. J Am Acad Child Adoles Psychiatry 2001; 40: 871-878.
18. Cahill C, Hanstock T, Jairam R, Hazell P, Walter G, Malhi GS. Comparison of diagnostic guidelines for juvenile bipolar disorder. Aust N Z J Psychiatry 2007; 41: 479-484.
19. Cooper JE, Kendell RE, Gurland BJ, Sharp L, Copeland JRM, Simon R. Psychiatric Diagnosis in New York and London. London: Oxford University Press, 1972.
20. Malhi GS, Green M, Fagiolini A, Peselow ED, Kumari V. Schizoaffective disorder: Diagnostic issues and future recommendations. Bipolar Disord 2008; 10: 215-230.
21. Goldberg D, Andrews G, Hobbs M. DSM-V & ICD-11: Where should bipolar disorder appear in the meta-structure? The Australian Society for Psychiatric Research (ASPR) Annual Conference 2008, Newcastle: Aust N Z J Psychiatry, 2008: A53.
22. Malhi GS. Et tu bipolar II? Acta Neuropsychiatrica 2007;19: 267-268.
23. Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord 2008; 10: 957-968.
24. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006; 163: 1905-1917.
25. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments. J Clin Psychiatry 1998; 59: 279-288.
26. Turner E, Matthews A, Lindardatos E, Tell R, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-260.
27. Kirsch I, Deacon B, Huedo-Medina T, Scoboria A, Moore T, Johnson B. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 2008; 5: e45.
28. Malhi GS. Upping the ante on antidepressants. Bipolar Disord 2008; 10: 975-978.
29. Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 1711-1722.
30. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008;117: 253-259.
31. Malhi GS, Berk M, Bourin M et al. Atypical mood stabilizers: A 'typical'role for atypical antipsychotics. Acta Psychiatr Scand 2005; 111: 29-38.
32. Malhi GS, Goodwin GM. The 'rise and fall'of mood stabilizers. Aust N Z J Psychiatry 2007; 41: 779-783.
33. Goodwin G, Malhi G. What is a mood stabilizer? Psychol Med 2007; 37: 609-614.
34. Healy D. Mania: A Short History of Bipolar Disorder. Baltimore: John Hopkins, 2008.
35. Harris M, Chandran S, Chakraborty N, Healy D. Mood-stabilizers: The acheology of the concept. Bipolar Disord 2003; 5: 446-452.
36. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352.
37. Cade JF, Malhi GS. Cade's Lithium. Acta Neuropsychiatrica 2007; 19: 125-126.
38. Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250-260.
39. Maggs R. Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963; 109: 59-65.
40. Goodwin FK, Murphy DL, Bunney WE Jr. Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. Arch Gen Psychiatry 1969; 21: 486-496.
41. Stokes PE, Shamoian CA, Stoll PM, Patton MJ. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; 1: 1319-1325.
42. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57: 187-190.
43. Prien RF, Caffey EM Jr, Klett CJ. A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1972; 27: 182-189.
44. Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972; 26: 146-153.
45. Braden W, Fink EB, Qualls CB, Ho CK, Samuels WO. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Res 1982; 7: 69-81.
46. Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-121.
47. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141-147.
48. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146-1154.
49. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacology 2004; 24: 599-606.
50. Tohen M, Chengappa KN, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62-69.
51. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: A systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442-455.
52. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67: 509-516.
53. Bierbrauer J, Nilsson A, Müller-Oerlinghausen B, Bauer M. Therapeutic and prophylactic effects of lithium on pathological aggression. In: Bauer M, Grof P, Müller-Oerlinghausen B eds. Lithium in Neuropsychiatry. UK: Informa Healthcare, 2006: 227-236.
54. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (Suppl. 4): 1-50.
55. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149: 108-111.
56. Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54: 37-42.
57. Carney SM, Goodwin GM. Lithium -a continuing story in the treatment of bipolar disorder. Acta Psychiatr Scand 2005; 111: 7-12.
58. Bhagwagar Z, Goodwin GM. The role of lithium in the treatment of bipolar depression. Clin Neurosci Res 2002; 2: 222-227.
59. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 5-69.
60. Bauer M, Ahrens B. Bipolar disorder. A practical guide to drug treatment. CNS Drugs 1996; 6: 35-52.
61. Fieve RR, Platman SR, Plutchik RR. The use of lithium in affective disorders. II. Prophylaxis of depression in chronic recurrent affective disorder. Am J Psychiatry 1968; 125: 492-498.
62. Greenspan K, Schildkraut JJ, Gordon EK, Baer L, Aronoff MS, Durell J. Catecholamine metabolism in affective disorders. 3. MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J Psychiatric Res 1970; 7: 171-183.
63. Goodwin FK, Murphy DL, Dunner DL, Bunney WE Jr. Lithium response in unipolar versus bipolar depression. Am J Psychiatry 1972; 129: 44-47.
64. Noyes R Jr, Dempsey GM. Lithium treatment of depression. Dis Nerv Syst 1974; 35: 573-576.
65. Mendels J. Lithium in the treatment of depression. Am J Psychiatry 1976; 133: 373-378.
66. Baron M, Gershon ES, Rudy V, Jonas WZ, Buchsbaum M. Lithium carbonate response in depression. Prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Arch Gen Psychiatry 1975; 32: 1107-1111.
67. Donnelly EF, Goodwin FK, Waldman IN, Murphy DL. Prediction of antidepressant responses to lithium. Am J Psychiatry 1978; 135: 552-556.
68. Malhi GS, Mitchell PB, Salim S. Bipolar Depression: Management options. CNS Drugs 2003; 17: 9-25.
69. Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: A meta-analysis. Br J Psychiatry 1991; 158: 666-675.
70. Watanabe S, Ishino H, Otsuki S. Double-blind comparison of lithium carbonate and imipramine in treatment of depression. Arch Gen Psychiatry 1975; 32: 659-668.
71. Khan MC. Lithium carbonate in the treatment of acute depressive illness. Bibl Psychiatr 1981; 161: 244-248.
72. Worrall EP, Moody JP, Peet M et al. Controlled studies of the acute antidepressant effects of lithium. Br J Psychiatry 1979; 135: 255-262.
73. Arieli A, Lepkifker E. The antidepressant effect of lithium. Curr Dev Psychopharmacolo 1981; 6: 165-190.
74. Khan MC, Wickham EA, Reed JV. Lithium versus placebo in acute depression: A clinical trial. Int Clin Psychopharmacolo 1987; 2: 47-54.
75. Mendels J, Secunda SK, Dyson WL. A controlled study of the antidepressant effects of lithium carbonate. Arch Gen Psychiatry 1972; 26: 154-157.
76. Kupfer DJ, Pickar D, Himmelhoch JM, Detre TP. Are there two types of unipolar depression? Arch Gen Psychiatry 1975; 32: 866-871.
77. Heit F, Nemeroff CB. Lithium augmentation of antidepressants in treatment-refractory depression. J Clin Psychiatry 1998; 59: 28-33.
78. Malhi GS, Adams D, Porter R et al. Clinical practice recommendations for depression. Acta Psychiatr Scand Suppl 2009; 439: 8-26.
79. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; 3: CD003013.
80. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-1733.
81. Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types of I and II bipolar disorders. Br J Psychiatry 2001; 41: S184-S190.
82. Berghofer A, Müller-Oerlinghausen B. No loss of efficacy after discontinuation and reinstitution of long-term lithium treatment? In: Gallicchio VS, Birch MJ eds. Lithium Biochemical and Clinical Advances. Cheshire, CT: Weidner Publishing Group, 1996: 39-46.
83. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489.
84. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
85. Bowden CL, Lecrubier Y, Bauer M et al. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord 2000; 59: S57-S67.
86. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: A prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065-1069.
87. Goodwin GM, Geddes JR. Latest maintenance data on lithium in bipolar disorder. Eur Neuropsychopharmacol 2003; 13: S51-s55.
88. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222.
89. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: A systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412.
90. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970; 117: 437-438.
91. Bradvik L, Mattisson C, Bogren M, Nettelbladt P. Long-term suicide risk of depression in the Lundby cohort 1947-1997-severity and gender. Acta Psychiatr Scand 2008; 117: 185-191.
92. Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 1991; 23: 1-7.
93. Müller-Oerlinghausen B, Ahrens B, Grof E et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992; 86: 218-222.
94. Müller-Oerlinghausen B, Wolf T, Ahrens B et al. Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. Acta Psychiatr Scand 1994; 90: 295-297.
95. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord 2006; 8: 625-639.
96. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819.
97. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380-383.
98. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-1088.
99. Schou M. Pharmacology and toxicology of lithium. Ann Rev Pharmacol Toxicol 1976; 16: 231-243.
100. Goodwin FK, Fireman B, Simon G, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 11: 1467-1473.
101. Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 103-107.
102. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60: 77-84 discussion 111-116.
103. Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann N Y Acad Sci 2001; 932: 24-38 discussion 9-43.
104. Nilsson A. The anti-aggressive actions of lithium. Rev Comtemp Pharmacother 1993; 4: 269-285.
105. Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001; 34: 132-136.
106. Linder J, FyröB, Petterson U, Werner S. Acute antidepressant effect of lithium associated with fluctuation of calcium and magnesium in plasma. Acta Psychiatr Scand 1989; 80: 27-36.
107. Ebert D, Jaspert A, Murata H, Kaschka WP. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients. Psychopharmacology 1995; 118: 223-225.
108. Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12: 2985-2992.
109. Bauer M, Forsthoff A, Baethge C et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2003; 253: 132-139.
110. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: A literature review and a proposal for a novel approach to improve practice. Psychother Psychosomat 2006; 75: 139-153.
111. Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: Double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; 2: 326-330.
112. Coppen A, Noguera R, Bailey J et al. Prophylactic lithium in affective disorders. Controlled trial. Lancet 1971; 2: 275-279.
113. Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 2006; 4: CD003492.
114. Maj M. Lithium prophylaxis of schizoaffective disorders: A prospective study. J Affective Disord 1988; 14: 129-135.
115. Prien RF, Caffey EM Jr, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1974; 31: 189-192.
116. Brockington IF, Kendell RE, Kellett JM, Curry SH, Wainwright S. Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 1978; 133: 162-168.
117. Miller FT, Libman H. Lithium carbonate in the treatment of schizophrenia and schizo-affective disorder: Review and hypothesis. Biol Psychiatry 1979; 14: 705-710.
118. Brockington IF, Wainwright S, Kendell RE. Manic patients with schizophrenic or paranoid symptoms. Psychol Med 1980; 10: 73-83.
119. Johnson G, Gershon S, Burdock EI, Floyd A, Hekimian L. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 1971; 119: 267-276.
120. Johnson G. Differential response to lithium carbonate in manic depressive and schizo-affective disorders. Dis Nerv Syst 1970; 31: 613-615.
121. Gershon S, Yuwiler A. Lithium ion: A specific psychopharmacological approach to the treatment of mania. J Neuropsychiat 1960; 1: 229-241.
122. Soares JC, Gershon S. The lithium ion: A foundation for psychopharmacological specificity. Neuropsychopharmacology 1998; 19: 167-182.
123. Shopsin B, Kim SS, Gershon S. A controlled study of lithium vs. chlorpromazine in acute schizophrenics. Br J Psychiatry 1971; 119: 435-440.
124. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007; 3: CD003834.
125. El-Mallakh R. Lithium Actions and Mechanisms. Washington, DC: American Psychiatric Press, 1996.
126. Atack J. Lithium, phosphatidylinositol signalling, and bipolar disorder: the role of inositol monophosphatase. In: Manji HK, Bowden CL, Belmaker RH eds. Bipolar Medications -Mechanisms of Action. Washington DC: American Psychiatric Press, 2000: 1-30.
127. Manji HK, Chen G, Hsaio JK, Masana MI, Moore GJ, WZ P. Regulation of signal transduction pathways by mood stabilizing agents. In: Manji HK, Bowden CL, Belmaker RH eds. Bipolar Medications -Mechanisms of Action. Washington DC: American Psychiatric Press, 2000: 129-177.
128. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008; 65: 255-263.
129. Zarate CA Jr, Singh JB, Carlson PJ et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: A pilot study. Bipolar Disord 2007; 9: 561-570.
130. Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009; 11 (Suppl. 2): 92-109.
131. Grof P. Responders to long-term lithium treatment. In: Bauer M, Grof P, Müller-Oerlinghausen B eds. Lithium in Neuropsychiatry: The Comprehensive Guide. UK: Informa Healthcare, 2006: 157-178.
132. Grof P, Müller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: The last 60 years. Bipolar Disord 2009; 11 (Suppl. 2): 10-19.